FT Options’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

FT Options’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-46,100	Closed	-$395K	–	281
2017 Q2	$395K	Buy	+46,100	New	+$1.85M	0.68%	37
2016 Q2	–	Sell	-59,600	Closed	-$1K	–	428
2016 Q1	$1K	Buy	+59,600	New	+$1.89M	﹤0.01%	288

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FT Options's PTLA Position: Q3 2017 in Review

FT Options sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 41,187 shares — an estimated $2.31M sold.

FT Options first reported a position in PTLA in Q1 2017 and held it in 2 quarters. The position peaked at $2.31M in Q2 2017. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

FT Options reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
FT Options sold 41,187 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $2.31M.
FT Options first reported a position in Portola Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
FT Options's Portola Pharmaceuticals, Inc. position peaked at $2.31M in Q2 2017.
221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.